Day 1 Wednesday, September 25, 2013 12:00 PM – 7:30 PM
AT&T Executive Education and Conference Center 1900 University Avenue Austin, Texas 78705

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 PM – 1:00 PM</td>
<td>Check-in</td>
<td>2nd Floor Conference Center Lobby</td>
</tr>
<tr>
<td>12:00 PM – 1:00 PM</td>
<td>Buffet Lunch</td>
<td>2nd Floor Tejas Conference Dining Room</td>
</tr>
<tr>
<td>1:00 PM – 1:05 PM</td>
<td>Welcome and Opening Remarks</td>
<td>Room 204</td>
</tr>
<tr>
<td>1:05 PM – 1:35 PM</td>
<td>General Session I – Keynote I</td>
<td>Room 204</td>
</tr>
<tr>
<td>1:35 PM – 3:30 PM</td>
<td>General Session II: Drug Discovery</td>
<td>Room 204</td>
</tr>
<tr>
<td></td>
<td>Co-Chairs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joseph Ready, PhD, Professor, Department of Biochemistry (UTSWMC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arturo Molina, MD, Vice President, Oncology Scientific Innovation California, Janssen R&amp;D/ Innovation Center, California (Johnson &amp; Johnson)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Concerted Biological and Chemical Approach to Pre-Clinical Drug Discovery at UT Southwestern Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bruce Posner, PhD, Associate Professor, Biochemistry, (UTSWMC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discovery and Pre-Clinical Development of Neuroprotective Small Molecules</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joseph Ready, PhD, Professor, Department of Biochemistry, (UTSWMC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>High-Throughput Pipeline for Novel Target Discovery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eric Boerwinkle, PhD, Professor &amp; Director, Division of Epidemiology &amp; Kozmetsky Family Chair in Human Genetics, (UTHSCH)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Institute for Applied Cancer Science, Developing the Next Generation of Oncology Agents for Targets Patient Populations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phil Jones, PhD, Head of Drug Discovery, MDACC’s Center’s Institute for Applied Cancer Science, (UTMDACC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>To Hold or Not to Hold the IND-A Potential Necessary Evil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Weitman, MD, PhD, Director, Institute for Drug Development, (UTHSCSA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>scuPA Pharmacotherapy for Lung and Pleural Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Idell, MD, PhD, Vice President for Research, (UTHSCT)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exchange Proteins Directly Activated by cAMP (EPACs) as Therapeutic Targets</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xiaodong Cheng, PhD, Professor, Department of Pharmacology and Toxicology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arturo Molina, MD, Vice President, Oncology Scientific Innovation California, Janssen R&amp;D/ Innovation Center, California (Johnson &amp; Johnson)</td>
<td></td>
</tr>
</tbody>
</table>
3:30 pm – 4:00 pm

**Break and Networking** *(coffee and refreshments)*

4:00 pm – 6:00 pm

**Concurrent Breakout Session I**

**Group #1**

**Room 106**

**Oncology**

**Co-Chairs**

Mien-Chie Hung, PhD, Vice President, Basic Research, Professor and Chair, Department of Molecular and Cellular Oncology, (UTMDACC)

Stephen Eck, MD, PhD, Vice President, Global Head of Medical Oncology Sciences, Astellas Pharma Global Development (Astellas)

**Speakers**

EGFR Modulates miRNA Maturation in Response to Hypoxia Through Phosphorylation of Ago 2

Mien-Chie Hung, PhD, Vice President, Basic Research, Professor and Chair, Department of Molecular and Cellular Oncology, (UTMDACC)

Developing New Medicines for Small Indications in Oncology - The Astellas Perspective

Stephen Eck MD, PhD, Vice President, Global Head of Medical Oncology Sciences, Astellas Pharma Global Development (Astellas)

Novel Microtubule Depolymerizing Agents with Efficacy in Murine Preclinical Models

Susan Mooberry, PhD, Professor of Pharmacology, (UTHSCSA)

Targeting HER3 for Cancer Therapy

Zhiqiang An, PhD, Professor of Molecular Medicine, Chair in Chemistry, and Director, Texas Therapeutics Institute, (UTHSCH)

The Use of Electronic Health Records (EHR) in Repurposing Drugs for Cancers

Hua Xu, PhD, Associate Professor, School of Biomedical Informatics, (UTHSCH)

The Law of Parsimony – Academic-Philanthropic-Industry Partnerships

Joseph Leveque, MD, Vice President, US Medical-Oncology (Bristol-Myers Squibb)

**Group #2**

**Room 301**

**Cardiovascular, Metabolic Disease**

**Chair**

Jonathan Cohen, PhD, Professor, Internal Medicine, (UTSWMC)

**Speakers**

ANGPTL8 Mediates a Metabolic Transition that Replenishes Adipose Tissue Triglyceride Stores

Jonathan Cohen, PhD, Professor, Internal Medicine, (UTSWMC)
Metabolic and Cardiovascular Diseases in a Cohort of Americans of Mexican Ancestry: Search for Biomarkers and Molecular Targets
Joseph McCormick, MD, Regional Dean and Professor, School of Public Health, (UTHSCH), and Vice President for South Texas Programs (UTHSCSA)

Development of Chrysalin®, a Unique Regenerative Peptide Drug, for Treatment of Vascular Disease, Myocardial Infarct, and Mitigating Effects of Radiation
Darrell Carney, PhD, Professor, Department of Biochemistry and Molecular Biology, (UTMB)

Using Mouse Genetics to Identify Circuits in the Brain Controlling Body Weight and Blood Glucose Levels
Joel Elmquist, DVM, PhD, Professor of Medical Science and Distinguished Chair in Medical Research, Departments of Internal Medicine and Pharmacology (UTSWMC)

Interaction Between Inflammatory and Metabolic Disease
Nicolas Musi, MD, Professor of Medicine, (UTHSCSA)

---

**Immunology and Biotherapeutics**

**Co-Chairs**
James P. Allison, PhD, Professor and Chair, Department of Immunology, (UTMDACC)
Sarah Bodary, PhD, New Ventures Business Lead, (Johnson & Johnson)

**Speakers**

**Imune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities**
James P. Allison, PhD, Professor and Chair, Department of Immunology, (UTMDACC)

**A Genomic Analysis of Susceptibility to Autoimmunity**
Edward Wakeland, PhD, Professor and Chairman, Department of Immunology, (UTSWMC)

John Reveille, MD, Professor of Internal Medicine, Director of the Division of Rheumatology and Clinical Immunogenetics, (UTHSCH)

**Discovery and Validation of Innate Immune Signatures**
Allan Brasier, MD, Director, Institute for Translational Sciences, (UTMB)

**Anti-cytokine Antibodies in Autoimmune Disease**
Sarah Bodary, PhD, New Ventures Business Lead, (Johnson & Johnson)

**Poster Session & Networking Reception** (Cash Bar)
Day 2 Thursday, September 26, 2013 8:00 am – 3:15 pm
AT&T Executive Education and Conference Center

7:30 am – 8:00 am
2nd Floor Conference Center Lobby

Check-in (continental breakfast)

8:00 am – 8:30 am
Room 204

General Session III – Keynote II
Barriers, Opportunities and Challenges to UT Academic-Industry Partnerships
Ronald DePinho, MD, President, (UTMDACC)

8:30 am – 9:30 am
10 minutes each; 10 minutes Q&A at the end of the session
Room 204

Insights into Industry – I
Chair
Beena Koshy, PhD, Special Consultant, Academia-Industry Partnerships, (UT System)

Speakers
A New R&D Eco-System: Centers for Therapeutic Innovation
Anthony Coyle, PhD, Vice President and Chief Scientific Officer of the Centers for Therapeutic Innovation (CTI), (Pfizer)

AbbVie Partnering and Collaboration Interests
Neela Patel, PhD, Director, Global External Research, (AbbVie)

Why is our Industry Struggling and What’s New in Partnering?
Michael Myers, PhD, Senior Director, Global External R&D, (Eli Lilly and Company)

The J&J Innovation Centers: Partnering with Academia and Entrepreneurs to Catalyze Innovation
Thorsten Melcher, PhD, Senior Director, New Ventures & Partnerships (Johnson & Johnson Innovation-Center)

An Introduction to GSK’s DPAc: Discovery Partnerships with Academia
Pearl Huang, PhD, Vice President and Global Head, Discovery Partnerships with Academia (DPAs) (GlaxoSmithKline)

9:30 am – 10:00 am
Break and Networking (coffee and refreshments)

10:00 am – 11:30 am
Concurrent Breakout Session II

15 minutes each
(includes Q&A)
<table>
<thead>
<tr>
<th>Group #4</th>
<th>Neuroscience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 107</td>
<td><strong>Co-Chairs</strong></td>
</tr>
<tr>
<td></td>
<td>Lisa Monteggia, PhD, Professor, Neuroscience, (UTSWMC)</td>
</tr>
<tr>
<td></td>
<td>Dale M. Edgar, PhD, Lilly Distinguished Research Fellow, VP Science and Technology Partnerships (Eli Lilly and Company)</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers</strong></td>
</tr>
<tr>
<td></td>
<td>Mechanism of Rapid Antidepressant Action</td>
</tr>
<tr>
<td></td>
<td>Lisa Monteggia, PhD, Professor, Neuroscience, (UTSWMC)</td>
</tr>
<tr>
<td></td>
<td>Unlocking Neuroscience Innovation in the 21st Century</td>
</tr>
<tr>
<td></td>
<td>Dale M. Edgar, PhD, Lilly Distinguished Research Fellow, VP Science and Technology Partnerships (Eli Lilly and Company)</td>
</tr>
<tr>
<td></td>
<td>Molecular Therapeutics for Neural Disorders</td>
</tr>
<tr>
<td></td>
<td>Kathryn Cunningham, PhD, Professor of Pharmacology, (UTMB)</td>
</tr>
<tr>
<td></td>
<td>Antidepressants: Targets for Novel Drugs</td>
</tr>
<tr>
<td></td>
<td>Wouter Koek, PhD, Professor of Psychiatry and Pharmacology, (UTHSCSA)</td>
</tr>
<tr>
<td></td>
<td>Acute Stroke Treatment</td>
</tr>
<tr>
<td></td>
<td>James Grotta, MD, Professor and Chairman, Department of Neurology, (UTHSCH)</td>
</tr>
<tr>
<td></td>
<td>Development of Novel Analgesic Drugs</td>
</tr>
<tr>
<td></td>
<td>Ken Hargreaves, DDS, PhD, Professor and Chair, Department of Endodontics, (UTHSCSA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group #5</th>
<th>Infectious Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 108</td>
<td><strong>Chair</strong></td>
</tr>
<tr>
<td></td>
<td>Herbert DuPont, MD, Professor, Medical Sciences and Director, Center for Infectious Disease, (UTHSCH)</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers</strong></td>
</tr>
<tr>
<td></td>
<td>The Intestinal Microbiome in Health and Disease</td>
</tr>
<tr>
<td></td>
<td>Herbert DuPont, MD, Professor, Medical Sciences and Director, Center for Infectious Disease, (UTHSCH)</td>
</tr>
<tr>
<td></td>
<td>Disarming Super-Bugs: Developing Anti-Adaptation Antibiotics</td>
</tr>
<tr>
<td></td>
<td>Cesar Arias, MD, PhD, Associate Professor of Medicine and Microbiology and Molecular Genetics, (UTHSCH)</td>
</tr>
<tr>
<td></td>
<td>QseC Small Molecule Inhibitors as a Novel Anti-Virulence Approach Against Gram-Negative Pathogens</td>
</tr>
<tr>
<td></td>
<td>Vanessa Sperandio, PhD, Professor, Department of Microbiology, Biochemistry, (UTSWMC)</td>
</tr>
<tr>
<td></td>
<td>Vaccine Development for Emerging Infectious Diseases</td>
</tr>
<tr>
<td></td>
<td>Scott Weaver, PhD, Professor, Department of Pathology, (UTMB)</td>
</tr>
</tbody>
</table>
Turnabout is Fair Play--The Use of the Bacterial Peptide MAM7 as an Antimicrobial Agent
Kim Orth, PhD, Professor, Department of Molecular Biology, Biochemistry, (UTSWMC)

The Vaccine Development Program at UTMB
Alan Barrett, PhD, Professor, Department of Pathology and Department of Microbiology & Immunology, Director, Sealy Center for Vaccine Development, (UTMB)

Group #6
Room 104

Biomarkers and Epigenetics
Co-Chairs
Robert Bast, MD, Vice President for Translational Research, (UTMDACC)
Meena Subramanyam, PhD, Vice President, Development Translational Medicine (Biogen Idec, Inc.)

Speakers
Biomarker Discovery for Early Detection
Samir Hanash, MD, PhD, Professor, Clinical Cancer Prevention–Research, (UTMDACC)

Personalized Medicine
Gordon Mills, MD, PhD, Chair, Systems Biology, (UTMDACC)

Chromatin Signaling
Sharon Dent, PhD, Professor and Chair, Department of Molecular Carcinogenesis, (UTMDACC)

DNA Methylation Biomarkers for Cancer Detection and Prognosis
Tim Huang, PhD, Professor and Chairman, Department of Molecular Medicine, (UTHSCSA)

Targets/Biomarkers from Academia to Industry
Meena Subramanyam, PhD, Vice President, Development Translational Medicine (Biogen Idec, Inc.)

11:30 am – 12:30 pm
10 minutes each;
10 minutes Q&A at the end of the session
Room 204

Insights into Industry – II:
Chair
Ferran Prat, JD, PhD, Vice President, Strategic Industry Ventures (UTMDACC)

Speakers
Scientific Engagement Models for Academic Entrepreneurs
Daniel Gant, PhD, Due Diligence/Consultancy Director, Scinovo, (GlaxoSmithKline)

Pfizer’s Approach to External Innovation
Ron Newbold, PhD, VP Strategic Research Partnerships, External R&D Innovation (Pfizer, Inc.)

Partnering at Merck
Sanjeev Munshi, PhD, Director, Worldwide Licensing and Acquisitions, (Merck)

The Science at AstraZeneca and the Role of Academic Partnerships
Donald Frail, PhD, Vice President, iScience, Emerging Innovations, (AstraZeneca)

Sanofi’s Approach to Building Productive Academic Partnerships
Sridaran Natesan, PhD, Vice President, External Innovation (R&D), (Sanofi Aventis)
Buffet Lunch

1:30 pm – 3:00 pm
Room 204

Academic–Industry Partnership Roundtable: Barriers, Opportunities and Recommendations

Co-Chairs
Patti Hurn, PhD, Vice Chancellor for Research and Innovation, (UT System)
Anthony Coyle, PhD, Vice President and Chief Scientific Officer of the Centers for Therapeutic Innovation (CTI), (Pfizer)

Panel: Members from UT and Industry
Bryan Allinson, Executive Director, Office of Technology Commercialization, (UT System)
Steve Bartz, PhD, Director, Worldwide Licensing, (Merck)
Bruce Butler, PhD, Vice President for Research and Technology, (UTHSCH)
Lynda Chin, MD, Professor and Chair, Genomic Medicine, (UTMDACC)
Donald Frail, PhD, Vice President, iScience, Emerging Innovations, (AstraZeneca)
David Gorenstein, PhD, Associate Dean for Research, School of Medicine and Chair, Department of NanoMedicine and Biomedical Engineering, (UTHSCH)
Frank Grassler, JD, Vice President for Technology Development, (UTSWMC)
Pearl Huang, PhD, Vice President and Global Head, Discovery Partnerships with Academia (DPAc), (GlaxoSmithKline)
Joseph Leveque, MD, Vice President, Head US Medical–Oncology (Bristol–Myers Squibb)
Stanton McHardy, PhD, Director, Center for Innovation in Drug Discovery and Associate Professor of Research, Department of Chemistry, (UTSA)
Thorsten Melcher, PhD, Senior Director, New Ventures & Partnerships, (Johnson & Johnson)
Lisa Monteggia, PhD, Professor, Neuroscience, (UTSWMC)
Michael Myers, PhD, Senior Director, Global External R&D, (Eli Lilly and Company)
Sridaran Natesan, PhD, Vice President, External Innovation (R&D), (Sanofi–Aventis)
Neela Patel, PhD, Director, Global External Research, (AbbVie)
Stan Watowich, PhD, Associate Professor, Department of Biochemistry and Molecular Biology, (UTMB)

3:00 pm – 3:15 pm
Room 204

Closing and Acknowledgements
Patti Hurn, PhD, Vice Chancellor for Research and Innovation, (UT System)

3:15 pm – 6:00 pm

Networking and Open Partnering Sessions Available

3:30 pm – 4:30 pm
Room 107

Concurrent External Advisory Board Meeting